STOCK TITAN
  1. Home
  2. News
  3. CVM

Cel-Sci Corp. - CVM STOCK NEWS

IMPACT
SENTIMENT
CVM : NYSE
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
IMPACT
SENTIMENT
CVM : NYSE
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
offering
IMPACT
SENTIMENT
CVM : NYSE
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
offering
IMPACT
SENTIMENT
CVM : NYSE
CEL-SCI Issues Letter to Shareholders
IMPACT
SENTIMENT
CVM : NYSE
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
clinical trial
IMPACT
SENTIMENT
CVM : NYSE
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
IMPACT
SENTIMENT
CVM : NYSE
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
IMPACT
SENTIMENT
CVM : NYSE
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
IMPACT
SENTIMENT
CVM : NYSE
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
IMPACT
SENTIMENT
CVM : NYSE
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
earnings
Stock CVM logo
Cel-Sci Corp.

NYSE:CVM

CVM Rankings

#4776 Ranked by Market Cap
#5028 Ranked by Stock Gains
N/A Ranked by Dividends

CVM Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Vienna

About CVM

cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.